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Tardive dyskinesia (TD) is one of the serious side effects of long-term antipsychotic
treatment. Chronic treatment with neuroleptic leads to the development of abnormal oral
movements called vacuous chewing movements (VCMs). The oxidative stress hypothesis
of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies
of this hypothesis indicate that neurotoxic free radical production is likely to be a conse-
quence of antipsychotic medication and is related to occurrence of TD. Oxidative stress is
implicated in the pathophysiology of TD. Rats chronically treated with haloperidol orally at
a dose of 0.2 mg/kg/day for a period of 5 weeks developed VCMs, which increased in a time-
dependent manner as the treatment continued for 5 weeks. Motor coordination impair-
ment started after the 1st week and was maximally impaired after 3 weeks and gradually
returned to the 1st week value. Motor activity in an open field or home cage (activity box)
not altered. Administration of rice bran oil (antioxidant) by oral tubes at a dose of 0.4 mL/
day prevented the induction of haloperidol-elicited VCMs as well impairment of motor
coordination. The results are discussed in the context of a protective role of antioxidant of
rice bran oil in the prevention of haloperidol-induced extrapyramidal symptoms.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
The therapeutic efficacy of antipsychotic drugs is generally
believed to be due to their ability to block central dopamine D2
receptor [1e3]. Haloperidol, a typical antipsychotic, is a buty-
rophenone that acts primarily as a D2 dopamine receptor
antagonist. Like most typical neuroleptics, haloperidol canir Syed University of Eng
.com.
ministration, Taiwan. Publcause extrapyramidal symptoms (EPS), including Parkin-
sonism and tardive dyskinesia (TD) [4].
TD, a syndrome of potently irreversible, involuntary hy-
perkinetic disorders that occurs during chronic neuroleptic
treatment, is a major limitation of neuroleptic therapy [5,6].
The development of TD can be attributed to the potential toxic
effects of prolonged typical neuroleptic administration. It has
been shown that high concentration of this dopamine D2ineering and Technology, Karachi-75300, Pakistan.
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could occur via an oxidative stress mechanism following the
production of inhibitors of mitochondrial respiration [8,9].
Oxidative stress is implicated in the pathophysiology of
various neurological disorders and also in development of TD
[10]. Chronic treatment with neuroleptics increases free
radical production and oxidative stress [11].
Rice bran is a brown layer present between rice and the
outer husk of the paddy. Rice bran stabilized by heat treat-
ment promptly aftermilling can be used as ingredients in food
processing because of its high nutrient content such as fiber,
lipid, protein, minerals, and tocopherols [12,13]. It is a good
source of vitamins [14,15] and has been utilized by the baking,
confectionary, and food-processing industries because of its
impressive nutritive values [12]. Rice bran consists of 12e23%
oil that has an unusually high unsaponifiable matter of 4%
concentration [16].
Rice bran oil (RBO) is an important derivative of rice. It has
some unique ingredients such as g-oryzanol, b-sitosterol, and
unesterified fatty acids, all of which may contribute to
cholesterol reduction [17e20]. RBO has a high content of
tocopherol and tocotrienol [21] with an antioxidant property
[22,23]. RBO is considered to be one of the most nutritious oils
due to its favorable fatty acid composition and unique com-
bination of naturally occurring biologically active antioxidant
compounds [22,23]. Inclusion of RBO in the diet has been
shown to improve the antioxiogenic potential and protect
against oxidative stress [24].
The objective of the present research was to determine the
effects of long-term intake of RBO designed to investigate the
effect of RBO on neuroleptic-induced EPS in rats.2. Materials and methods
2.1. Animals
Locally bred male albino Wistar rats weighing 180e220 g
purchased from HEJ Research Institute, University of Karachi,
Pakistanwere housed individually with free access to cubes of
standard rodent diet and tap water 3 days before starting the
experiment.2.2. Drugs
Haloperidol (Serenace; G.D. Searle, Peapack, NJ, USA) pur-
chased as oral drops of 2.0 mg/ml was given orally in drinking
water at a dose of 0.2 mg/kg/day. RBO was extracted by the
method of Hu et al [25] and given orally by oral tubes at a dose
of 0.4 mL/day.2.3. Experimental protocol
Sixteen animals were divided into four groups: (1) waterþ-
water; (2) waterþRBO (3) haloperidolþwater; and (4) haloper-
idolþRBO. They received the respective treatment for 5 weeks.
Vacuous chewing movements (VCMs), motor coordination,
exploratory activity in an open field and in a home cage were
monitored weekly for 5 weeks.2.4. Behavioral analysis
2.4.1. Open field activity
To monitor activity in a novel environment, an open field
apparatus was used, consisting of a square area 76 cm 76 cm
with walls 42 cm high. The floor was divided by lines into 25
equal squares. To determine activity, a rat was placed in the
center square of the open field. The numbers of squares
crossed with all four paws were scored for 5 minutes.
2.4.2. Home cage activity
To monitor activity in a familiar environment, activity boxes
were used. The rectangular Perspex activity cage consisted of
small square area (26 cm  26 cm  26 cm) with sawdust-
covered floor. Before monitoring the activity an animal was
placed in it for 15 minutes for habituation. Numbers of
crossings across the box were monitored for 10 minutes.
2.4.3. Rota-rod activity
Motor coordinationwas assessed for all rats on a rota-rod. The
rota-rod had a 7 cm radius and a speed of 16 revolutions/
minute. Prior to any treatment rats were trained in a single
session until they attained 150 seconds on the rota-rod.
2.4.4. VCM quantification
Animals were placed individually in an activity box
(26 cm  26 cm  26 cm) with sawdust-covered floor and were
allowed to adapt the observation cage for a period of 15 mi-
nutes. VCMs were monitored during a 10-minute observation
period. For calculation purposes, each burst of purposeless
chewing was counted as one, if its duration was at least 3
seconds.
2.5. Statistical analysis
Data were analyzed by three-way ANOVA. Posthoc comparison
was done by NewmaneKeuls test with p < 0.05 taken as
significant.3. Results
Fig. 1 shows the effect of administration of haloperidol on
activity in an open field in animal treated with water and RBO.
Data analyzed by three-way ANOVA showed significant ef-
fects of haloperidol (F ¼ 6.75; df ¼ 1,60; p < 0.05), weeks
(F ¼ 39.14; df ¼ 4,60; p < 0.01), and RBO (F ¼ 11.36; df ¼ 1,60;
p < 0.01). Interactions between haloperidol and weeks
(F ¼ 1.87; df ¼ 4,60; p > 0.05), haloperidol and RBO (F ¼ 2.15;
df¼ 4,60; p > 0.05), RBO andweeks (F¼ 1.07; df¼ 4,60; p > 0.05),
and haloperidol, weeks, and RBO (F ¼ 2.02; df ¼ 4,60; p > 0.05)
were not significant. Differences by NewmaneKeuls test were
not significant.
Fig. 2 shows the effect of administration of haloperidol on
activity in a home cage (activity box) in animals treated with
water and RBO. Data analyzed by three-way ANOVA showed
significant effects of haloperidol (F ¼ 8.13; df ¼ 1,60; p < 0.01),
weeks (F ¼ 14.21; df ¼ 4,60; p < 0.01), and RBO (F ¼ 40.81;
df ¼ 1,60; p < 0.01). Interactions between haloperidol and
weeks (F ¼ 1.60; df ¼ 4,60; p > 0.05), haloperidol and RBO
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Fig. 2 e Effects of administration of haloperidol on activity
in a home cage (activity box) in animals treated with water
and rice bran oil (RBO). Values are means ± standard
deviation (n ¼ 4).
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Fig. 1 e Effects of administration of haloperidol on activity
in an open field in animals treated with water and rice bran
oil (RBO). Values are means ± standard deviation (n ¼ 4).
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df ¼ 4,60; p > 0.05), and haloperidol, weeks, and RBO (F ¼ 0.92;
df ¼ 4,60; p > 0.05) were not significant. Differences by New-
maneKeuls test were not significant.
Fig. 3 shows the effect of administration of haloperidol on
motor coordination in animals treated with water and RBO.
Data analyzed by three-way ANOVA showed significant ef-
fects of haloperidol (F ¼ 261.71; df ¼ 1,60; p < 0.01), weeks
(F ¼ 4.11; df ¼ 4,60; p < 0.01), and RBO (F ¼ 147.89; df ¼ 1,60;
p < 0.01). Interactions between haloperidol and weeks
(F ¼ 4.11; df ¼ 4,60; p < 0.01), haloperidol and RBO (F ¼ 4.11;
df¼ 4,60; p < 0.01), RBO andweeks (F¼ 3.43; df¼ 4,60; p < 0.05),
and haloperidol, weeks, and RBO (F ¼ 3.43; df ¼ 4,60; p < 0.05)
were significant. Posthoc analysis by NewmaneKeuls test
showed that administration of haloperidol impaired motor
coordination after the 1st week. The impairment of motor
coordination was maximum after the 3rd week and gradually
returned to 1st week value. Administration of RBO prevented
the haloperidol-induced impairment of motor coordination.
Fig. 4 shows the intensity of haloperidol-induced VCMs in
animals treated with water and RBO. Data analyzed by three-
way ANOVA showed significant effects of haloperidol
(F ¼ 344.39; df ¼ 1,60; p < 0.01), weeks (F ¼ 25.29; df ¼ 4,60;
p < 0.01), and RBO (F ¼ 227.35; df ¼ 1,60; p < 0.01). Interactions
between haloperidol and weeks (F ¼ 14.12; df ¼ 4,60; p < 0.01),
haloperidol and RBO (F ¼ 278.98; df ¼ 4,60; p < 0.01), RBO and
weeks (F ¼ 24.78; df ¼ 4,60; p < 0.01), and haloperidol, weeks,
and RBO (F ¼ 23.11; df ¼ 4,60; p < 0.01) were significant. Posthoc0
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Fig. 3 e Effect of administration of haloperidol on motor
coordination in animals treated with water and rice bran
oil (RBO). Values are means ± standard deviation (n ¼ 4).
Significant differences by NewmaneKeuls test: *p < 0.01
from haloperidol plus water-treated animals, þp < 0.01
from water-treated animals following three-way ANOVA.
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Fig. 4 e Intensity of haloperidol-induced vacuous chewing
movements in animals treated with water and rice bran oil
(RBO). Values are means ± standard deviation (n ¼ 4).
Significant differences by NewmaneKeuls test: *p < 0.01
from haloperidol plus water-treated animals, þp < 0.01
from water-treated animals following three-way ANOVA.
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of haloperidol elicited VCMS for 2 weeks, which increased in a
time-dependent manner for 3e5 weeks. Administration of
RBO prevented the induction of haloperidol-elicited VCMs.4. Discussion
The major findings of the present study were that chronic
administration of haloperidol increased VCMs in a time-
dependent manner and impaired motor coordination as
treatment continued for 5 weeks. Motor activity was not
altered by oral repeated haloperidol treatment. The aim of the
present study was to investigate the effect of RBO on
haloperidol-induced EPS. Results show that RBO prevented
the induction of haloperidol-elicited VCMs as well impair-
ment of motor coordination.
An unbalanced production of free radicals is associated
with chronic neuroleptic use [26] and might contribute to the
onset of TD [27] and other movement disorders, such as dys-
tonia and Parkinsonism [28].
Neuroleptics act by blocking dopamine receptors [29] and
increase the turnover and metabolism of dopamine, which in
turn could lead to an increased production of hydrogen
peroxide [30,31], resulting in oxidative stress [32]. Dopamine is
primarily metabolized through oxidation by monoamine oxi-
dase to 3,4-dihydroxyphenyl acetic acid. This reactionproduces hydrogen peroxide. Dopamine is also metabolized
by auto-oxidation, yielding superoxide radical. Increased
dopamine turnover by neuroleptics could lead to excessive
production of these potentially damaging free radicals [33].
Oxygen free radicals are also reported to diminish the dopa-
mine transporter function further increasing the extracellular
dopamine levels [34].
Neuroleptics suppress the activity of certain detoxifying
enzymes, leaving cells unprotected, especially if basal enzyme
activity is low or the free radical-scavenging mechanism are
less effective. Free radicals are highly reactive with specific
cellular components and have cytotoxic properties [35] and
neuronal loss in the striatum has been reported in animals
treated with neuroleptics [36].
Oxidative stress in the hippocampus might inhibit
neuronal plasticity and neurogenesis [37] and the behavioral
deficits by antipsychotics may bemediated by oxidative stress
[9]. Neuroleptics may also have direct cytotoxic effect via the
production of toxic metabolites [38]. Reduced haloperidol is
oxidized to a pyridinum metabolite in blood and brain [39],
which is also thought to be a mitochondrial toxin. As reduced
haloperidol concentrations are about five times higher in the
elderly [40]; this could contribute to their predisposition to
develop TD. It is well known that the antipsychotic drug
haloperidol causes VCMs in rats, which are representative of
side effects of TD. Haloperidol was disclosed to potentiate
increases in oxidative stress or free radical-mediated levels of
toxic metabolites in rat. Antioxidant has been used to combat
haloperidol-induced VCMs in rats resulting from increases in
oxidative cellular events [41]. Much preclinical evidence sug-
gests that the inclusion of a naturally occurring and benign
antioxidant compound as an adjunct to antipsychotics treat-
ment may help guard patients against TD [42,43].
In the present study, activity in an open field and home
cage were not altered by oral repeated haloperidol adminis-
tration (Figs. 1 and 2). Chronic haloperidol treated animals
exhibited VCMs for 2 weeks, which increased in a time
dependent manner for 3e5 weeks (Fig. 3) and motor coordi-
nation was also impaired (Fig. 4), suggesting possible induc-
tion of free radical generation by chronic haloperidol
treatment involved in the increase frequencies of VCMs and
impairment of motor coordination.
RBO inhibited lipid peroxidation in erythrocytes and in all
tissues initiated by free radical generation [19]. Antioxidants,
such as tocopherol, tocotrienol, g-oryzanol, and polyphenol
and their components are present in rice bran. These com-
pounds are free radical scavengers [16] and are normally
consumed when tissues are exposed to oxidative stress [44]
and protect neuronal cell from injury induced by oxygen free
radicals in vitro and ischemiaereperfusion damage in vivo [45].
Toxicological studies show that intake of cellulose derived
from agricultural waste such asmaize cob, groundnut shell, or
rice husks increased locomotor activity [46]. Similarly, stan-
dard rice bran diet increases exploratory activity in a novel
environment [47]. In the present study motor activity was not
altered by RBO.
The antioxidant activities of the four of the vitamin E and
three oryzanol components purified from rice bran were
investigated in a chronic model of cholesterol oxidation. All
components exhibited significant antioxidant capacity and
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 3 7 0e3 7 5374inhibited cholesterol oxidation [48]. Previously, it was re-
ported that vitamin E has neuroprotective properties [49,50]
and may be of use for the treatment TD [51].
TD is a serious motor disorder related to antipsychotic
therapy, whose pathophysiology is associated to oxidative
stress [52]. Previous studies have shown that administration
of B vitamins (B1:B6:B12 at 60:60:0.6 mg/kg) alone or the
vitamin B cocktail along with haloperidol [52] and extract of
Ginkgo biloba (antioxidant) and vitamin E [53] prevent the
development of orofacial dyskinesia.
The findings of the present study support the notion that
oxidative stress is involved in the elicitation of neuroleptic-
induced VCMs and show that RBO given orally at a dose of
0.4 mL/day prevents the haloperidol-induced VCMs as well as
impairment of motor coordination. It is suggested that anti-
oxidant action of RBO is involved in the reversal of
haloperidol-induced EPS.Conflicts of interest
The author declares that there are no conflicts of interest.
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